$CLGN News

CollPlant Biotechnologies Q1 Adj. EPS $(0.21) Misses $(0.19) Estimate, Sales $73.000K Miss $1.100M Estimate

CollPlant Biotechnologies shares are trading lower after the company announced the termination of its development agreement with AbbVie.

CollPlant Biotechnologies shares are trading lower after the company announced the termination of its development agreement with AbbVie.

CollPlant Biotechnologies Announces Termination Of Development Agreement With AbbVie, Issues Letter to Shareholders, Will Reduce Headcount By 50%

CollPlant Biotechnologies (NASDAQ:CLGN) Stock Surges on Q4 Revenue Beat

CollPlant Biotechnologies shares are trading lower after the company reported worse-than-expected Q4 financial results.

CollPlant Biotechnologies Q4 Adj. EPS $(0.25) Misses $(0.19) Estimate, Sales $60.000K Miss $1.524M Estimate

CollPlant Biotechnologies Q4 Adj. EPS $(0.25) Misses $(0.19) Estimate, Sales $60.000K Miss $1.524M Estimate.

CollPlant Biotechnologies Receives Nasdaq Noncompliance Notice, Gets Time Through Sept. 21 To Regain Compliance

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

CollPlant Biotechnologies Announced Korean Patent Allowance Secured for Its Photocurable Dermal Filler

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

CollPlant Announces Launch Of BioFlex, Ready-To-Print rhCollagen-Based Kit For Digital Light Processing 3D Bioprinting Applications

CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments

CollPlant Positions Photocurable rhCollagen Dermal Filler Platform To Address Facial Volume Loss Linked To Rapid Weight Reduction Including GLP-1 Therapy Patients

When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Turn A Profit?

CollPlant to sell 1.6M ordinary shares at $1.25 in registered direct offering

D. Boral Capital Downgrades CollPlant Biotechnologies to Hold

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING

CollPlant Biotechnologies shares are trading lower. The company announced a $2 million registered direct offering.